Tonix Pharmaceuticals Holding Corp. (TNXP)
NASDAQ: TNXP · Real-Time Price · USD
22.49
-0.51 (-2.22%)
At close: Oct 8, 2025, 4:00 PM EDT
22.49
0.00 (0.00%)
After-hours: Oct 8, 2025, 7:22 PM EDT
TNXP Employees
Tonix Pharmaceuticals Holding had 81 employees as of December 31, 2024. The number of employees decreased by 22 or -21.36% compared to the previous year.
Employees
81
Change (1Y)
-22
Growth (1Y)
-21.36%
Revenue / Employee
$121,370
Profits / Employee
-$1,005,210
Market Cap
197.15M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 81 | -22 | -21.36% |
| Dec 31, 2023 | 103 | -14 | -11.97% |
| Dec 31, 2022 | 117 | 44 | 60.27% |
| Dec 31, 2021 | 73 | 47 | 180.77% |
| Dec 31, 2020 | 26 | 10 | 62.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
TNXP News
- 8 days ago - Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Ganesh Kamath as Head of Market Access - GlobeNewsWire
- 9 days ago - Tonix Pharmaceuticals Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900 (Intranasal Potentiated Oxytocin) in 2026 - GlobeNewsWire
- 20 days ago - Tonix Pharmaceuticals Announces Positive Pre-IND Meeting with FDA for TNX-102 SL for the Treatment of Major Depressive Disorder - GlobeNewsWire
- 21 days ago - Tonix Pharmaceuticals Announces In-licensing Phase 2/3-Ready Monoclonal Antibody Designed for Seasonal Prevention of Lyme Disease (TNX-4800) - GlobeNewsWire
- 4 weeks ago - Tonix Pharmaceuticals Presents Clinical Data on Tonmya™ for the Treatment of Fibromyalgia at PAINWEEK 2025 - GlobeNewsWire
- 5 weeks ago - Tonix Pharmaceuticals to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2025 - GlobeNewsWire
- 7 weeks ago - Tonix Pharmaceuticals Soars, Then Sinks: What's Next After Tonmya's Approval (Upgrade) - Seeking Alpha
- 7 weeks ago - Tonix Secures Fibromyalgia Approval - What Investors Should Know - Seeking Alpha